Seeking Alpha

Alder files for $115M IPO

Alder Biopharmaceuticals has filed to raise up to $115M in an IPO on Nasdaq.

The company develops anti-bodies for treating a range of conditions, and its pipeline includes Clazakizumab, which the the company is developing with Bristol-Myers Squipp for Rheumatoid Arthritis, and ALD403 for migraines.

Alder posted losses of $20.6M in 2013.

The company intends to trade under the ticker symbol ALDR.



From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs